Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry. PFE Stock Underperforms ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t ...

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high ...

Pfizer has been a big name in healthcare for decades, but it has been a largely underwhelming investment over the past 10 ...

Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its stock performance over the recent years.

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock here.